|
1
|
Alonso-Gordoa T, Díez JJ, Durán M and
Grande E: Advances in thyroid cancer treatment: Latest evidence and
clinical potential. Ther Adv Med Oncol. 7:22–38. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hegedüs L: Clinical practice. The thyroid
nodule. N Engl J Med. 351:1764–1771. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
GLOBOCAN 2012 [Internet]. Available from:
urihttp://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=89356&title=India&sex=0&type=0&window=1&sort=0&submit=%C2%A0Execute%C2%A0simplehttp://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=89356&title=India&sex=0&type=0&window=1&sort=0&submit=%C2%A0Execute%C2%A0.
Accessed September 10, 2018.
|
|
4
|
Leenhardt L, Bernier MO, Boin-Pineau MH,
Conte Devolx B, Maréchaud R, Niccoli-Sire P, Nocaudie M, Orgiazzi
J, Schlumberger M, Wémeau JL, et al: Advances in diagnostic
practices affect thyroid cancer incidence in France. Eur J
Endocrinol. 150:133–139. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Benbassat CA, Mechlis-Frish S and Hirsch
D: Clinicopathological characteristics and long-term outcome in
patients with distant metastases from differentiated thyroid
cancer. World J Surg. 30:1088–1095. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Durante C, Haddy N, Baudin E, Leboulleux
S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De
Vathaire F and Schlumberger M: Long-term outcome of 444 patients
with distant metastases from papillary and follicular thyroid
carcinoma: Benefits and limits of radioiodine therapy. Clin
Endocrinol Metab. 91:2892–2899. 2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cabanillas ME, Patel A, Danysh BP, Dadu R,
Kopetz S and Falchook G: BRAF Inhibitors: Experience in thyroid
cancer and general review of toxicity. Horm Cancer. 6:21–36.
2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Worden F: Treatment strategies for
radioactive iodine-refractory differentiated thyroid cancer. Ther
Adv Med Oncol. 6:267–279. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cabanillas ME, Schlumberger M, Jarzab B,
Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner
DL, Topliss D, et al: A phase 2 trial of lenvatinib (E7080) in
advanced, progressive, radioiodine-refractory, differentiated
thyroid cancer: A clinical outcomes and biomarker assessment.
Cancer. 121:2749–2756. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Brose MS, Nutting CM, Jarzab B, Elisei R,
Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R,
Shong YK, et al: Sorafenib in radioactive iodine-refractory,
locally advanced or metastatic differentiated thyroid cancer: A
randomised, double-blind, phase 3 trial. Lancet. 384:319–328.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Schlumberger M, Tahara M, Wirth LJ,
Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff
AO, et al: Lenvatinib versus placebo in radioiodine-refractory
thyroid cancer. N Engl J Med. 372:621–630. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
St Bernard R, Zheng L, Liu W, Winer D, Asa
SL and Ezzat S: Fibroblast growth factor receptors as molecular
targets in thyroid carcinoma. Endocrinology. 146:1145–1153.
2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Boelaert K, McCabe CJ, Tannahill LA,
Gittoes NJL, Holder RL, Watkinson JC, Bradwell AR, Sheppard MC and
Franklyn JA: Pituitary tumor transforming gene and fibroblast
growth factor-2 expression: Potential prognostic indicators in
differentiated thyroid cancer. J Clin Endocrinol Metab.
88:2341–2347. 2003.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Kim KB, Chesney J, Robinson D, Gardner H,
Shi MM and Kirkwood JM: Phase I/II and pharmacodynamic study of
dovitinib (TKI258), an inhibitor of fibroblast growth factor
receptors and VEGF receptors, in patients with advanced melanoma.
Clin Cancer Res. 17:7451–7461. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tahara M, Schlumberger M, Elisei R, Habra
MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic
M, et al: Exploratory analysis of biomarkers associated with
clinical outcomes from the study of lenvatinib in differentiated
cancer of the thyroid. Eur J Cancer. 75:213–221. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Stjepanovic N and Capdevila J: Multikinase
inhibitors in the treatment of thyroid cancer: Specific role of
lenvatinib. Biologics. 8:129–139. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Durante C, Puxeddu E, Ferretti E, Morisi
R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A,
et al: BRAF mutations in papillary thyroid carcinomas inhibit genes
involved in iodine metabolism. J Clin Endocrinol Metab.
92:2840–2843. 2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cabanillas ME, McFadden DG and Durante C:
Thyroid cancer. Lancet. 388:2783–2795. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lamartina L, Ippolito S, Danis M, Bidault
F, Borget I, Berdelou A, Al Ghuzlan A, Hartl D, Blanchard P,
Terroir M, et al: Antiangiogenic tyrosine kinase inhibitors:
Occurrence and risk factors of hemoptysis in refractory thyroid
cancer. J Clin Endocrinol Metab. 101:2733–2741. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Blevins DP, Dadu R, Hu M, Baik C,
Balachandran D, Ross W, Gunn B and Cabanillas ME: Aerodigestive
fistula formation as a rare side effect of antiangiogenic tyrosine
kinase inhibitor therapy for thyroid cancer. Thyroid. 24:918–922.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ho AL, Grewal RK, Leboeuf R, Sherman EJ,
Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane
S, et al: Selumetinib-enhanced radioiodine uptake in advanced
thyroid cancer. N Engl J Med. 368:623–632. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Rothenberg SM, McFadden DG, Palmer EL,
Daniels GH and Wirth LJ: Redifferentiation of iodine-refractory
BRAF V600E-mutant metastatic papillary thyroid cancer with
dabrafenib. Clin Cancer Res. 21:1028–1035. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Leboulleux S, Bastholt L, Krause T, de la
Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F,
Leenhardt L, Soufflet C, et al: Vandetanib in locally advanced or
metastatic differentiated thyroid cancer: A randomised,
double-blind, phase 2 trial. Lancet Oncol. 13:897–905.
2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bible KC, Cote GJ, Demeure MJ, Elisei R,
Jhiang S and Ringel MD: International Thyroid Oncology Group
Correlative Science Committee. Correlative studies in clinical
trials: A position statement from the international thyroid
oncology group. J Clin Endocrinol Metab. 100:4387–4395.
2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gupta-Abramson V, Troxel AB, Nellore A,
Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT,
Loevner LA, O'Dwyer PJ and Brose MS: Phase II trial of sorafenib in
advanced thyroid cancer. J Clin Oncol. 26:4714–4719.
2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kloos RT, Ringel MD, Knopp MV, Hall NC,
King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, et al:
Phase II trial of sorafenib in metastatic thyroid cancer. J Clin
Oncol. 27:1675–1684. 2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Schneider TC, Abdulrahman RM, Corssmit EP,
Morreau H, Smit JW and Kapiteijn E: Long-term analysis of the
efficacy and tolerability of sorafenib in advanced radio-iodine
refractory differentiated thyroid carcinoma: Final results of a
phase II trial. Eur J Endocrinol. 167:643–650. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ahmed M, Barbachano Y, Riddell A, Hickey
J, Newbold KL, Viros A, Harrington KJ, Marais R and Nutting CM:
Analysis of the efficacy and toxicity of sorafenib in thyroid
cancer: A phase II study in a UK based population. Eur J
Endocrinol. 165:315–322. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Keefe SM, Troxel AB, Rhee S, Puttaswamy K,
O'Dwyer PJ, Loevner LA, Mandel J and Brose MS: Phase II trial of
sorafenib in patients with advanced thyroid cancer. J Clin Oncol.
29 (Suppl 15)(S5562)2011.
|
|
32
|
Hoftijzer H, Heemstra KA, Morreau H,
Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM,
Huijberts M, Kapiteijn E, et al: Beneficial effects of sorafenib on
tumor progression, but not on radioiodine uptake, in patients with
differentiated thyroid carcinoma. Eur J Endocrinol. 161:923–931.
2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sherman SI, Jarzab B, Cabanillas ME,
Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J,
Shah MH, et al: A phase II trial of the multitargeted kinase
inhibitor E7080 in advanced radioiodine (RAI)-refractory
differentiated thyroid cancer (DTC). J Clin Oncol. 29 (15
Suppl)(S5503)2011.
|
|
34
|
Sherman EJ, Ho AL, Fury MG, Baxi SS, Haque
S, Korte SH, Smith-Marrone S, Xiao H, Ghossein RA, Fagin JA, et al:
A phase II study of temsirolimus/sorafenib in patients with
radioactive iodine (RAI)-refractory thyroid carcinoma. J Clin
Oncol. 30 (15 Suppl)(S5514)2012.
|
|
35
|
Sherman EJ, Ho AL, Fury MG, Baxi SS, Haque
S, Lipson BL, Kurz S, Fagin JA and Pfister DG: Phase II study of
everolimus and sorafenib for the treatment of metastatic thyroid
cancer. J Clin Oncol. 31 (Suppl 15)(S6024)2013.
|
|
36
|
Hong DS, Cabanillas ME, Wheler J, Naing A,
Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El
Naggar AK, et al: Inhibition of the Ras/Raf/MEK/ERK and RET kinase
pathways with the combination of the multikinase inhibitor
sorafenib and the farnesyltransferase inhibitor tipifarnib in
medullary and differentiated thyroid malignancies. J Clin
Endocrinol Metab. 96:997–1005. 2011.PubMed/NCBI View Article : Google Scholar
|
